Last reviewed · How we verify

Injection of methylprednisolone

Centre Hospitalier Universitaire Dijon · Phase 3 active Small molecule

Methylprednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting pro-inflammatory cytokine production and immune cell activation.

Methylprednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting pro-inflammatory cytokine production and immune cell activation. Used for Inflammatory and autoimmune disorders (specific indication in phase 3 trial not specified in provided data).

At a glance

Generic nameInjection of methylprednisolone
SponsorCentre Hospitalier Universitaire Dijon
Drug classCorticosteroid
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

Methylprednisolone binds to glucocorticoid receptors in the cytoplasm, translocates to the nucleus, and modulates gene transcription to decrease production of inflammatory mediators (IL-1, IL-6, TNF-α) and reduce immune cell proliferation and migration. This broad immunosuppressive and anti-inflammatory action makes it useful across multiple inflammatory and autoimmune conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: